Insider Selling: Shuttle Pharmaceuticals (NASDAQ:SHPH) Major Shareholder Sells $35,231.40 in Stock

Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ:SHPH) major shareholder Financial Lp Hrt sold 10,580 shares of the firm’s stock in a transaction dated Tuesday, July 7th. The shares were sold at an average price of $3.33, for a total value of $35,231.40. Following the completion of the sale, the insider owned 70,805 shares of the company’s stock, valued at approximately $235,780.65. This represents a 13.00% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Large shareholders that own more than 10% of a company’s shares are required to disclose their transactions with the SEC.

Financial Lp Hrt also recently made the following trade(s):

• On Wednesday, July 8th, Financial Lp Hrt sold 18,531 shares of Shuttle Pharmaceuticals stock. The shares were sold at an average price of $3.52, for a total value of $65,229.12.
• On Monday, July 6th, Financial Lp Hrt sold 9,022 shares of Shuttle Pharmaceuticals stock. The stock was sold at an average price of $3.51, for a total value of $31,667.22.
• On Thursday, July 2nd, Financial Lp Hrt purchased 7,851 shares of Shuttle Pharmaceuticals stock. The stock was purchased at an average price of $3.54 per share, for a total transaction of $27,792.54.
• On Wednesday, July 1st, Financial Lp Hrt acquired 3,959 shares of Shuttle Pharmaceuticals stock. The stock was purchased at an average cost of $3.30 per share, with a total value of $13,064.70.
• On Tuesday, June 30th, Financial Lp Hrt acquired 6,755 shares of Shuttle Pharmaceuticals stock. The stock was purchased at an average cost of $3.23 per share, with a total value of $21,818.65.
• On Monday, June 29th, Financial Lp Hrt acquired 25,836 shares of Shuttle Pharmaceuticals stock. The shares were purchased at an average price of $3.44 per share, with a total value of $88,875.84.

Shuttle Pharmaceuticals Price Performance

Shares of NASDAQ:SHPH traded down $0.29 during trading on Thursday, reaching $3.28. 125,987 shares of the stock were exchanged, compared to its average volume of 555,046. Shuttle Pharmaceuticals Holdings, Inc. has a 1-year low of $2.90 and a 1-year high of $55.90. The stock has a fifty day moving average of $5.30 and a two-hundred day moving average of $10.27. The firm has a market cap of $2.10 million, a price-to-earnings ratio of -0.07 and a beta of 0.29.

Analysts Set New Price Targets

Several research analysts have weighed in on the stock. Weiss Ratings upgraded shares of Shuttle Pharmaceuticals from a “sell (e)” rating to a “sell (e+)” rating in a report on Tuesday, June 30th. Wall Street Zen raised shares of Shuttle Pharmaceuticals to a “sell” rating in a research report on Saturday, July 4th. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, Shuttle Pharmaceuticals presently has an average rating of “Sell”.

Institutional Investors Weigh In On Shuttle Pharmaceuticals

Institutional investors have recently bought and sold shares of the stock. Connective Capital Management LLC purchased a new stake in Shuttle Pharmaceuticals in the 3rd quarter valued at $357,000. Ikarian Capital LLC purchased a new position in Shuttle Pharmaceuticals during the 4th quarter worth $124,000. Boothbay Fund Management LLC purchased a new position in Shuttle Pharmaceuticals during the 4th quarter worth $37,000. Finally, Geode Capital Management LLC bought a new stake in shares of Shuttle Pharmaceuticals in the 4th quarter worth $26,000. Institutional investors own 4.58% of the company’s stock.

Shuttle Pharmaceuticals Company Profile

Shuttle Pharmaceuticals Holdings, Inc, a clinical stage pharmaceutical company, develops novel therapies to cure cancers. It develops Ropidoxuridine, an oral halogenated pyrimidine to treat patients with brain tumors and sarcomas SP-1-161, an HDAC inhibitor that initiates the mutated in ataxia-telangiectasia response pathway for radiation sensitizing cancer cells and protecting normal cells; SP-2-225, a pre-clinical class IIb that effects on the regulation of the immune system; and SP-1-303, a pre-clinical selective Class I HDAC for the treatment of ER positive cancers .